[1]
|
C. Scarpignato and I. Pelosini, “Review Article: The Opportunities and Benefits of Extended Acid Suppression Aliment,” Pharmacology and Therapeutics, Vol. 23, No. S2, 2006, pp. 23-34.
|
[2]
|
J. Guan, J. Yang, Y. Bi, S. Shi and F. Li, “Chiral Separation of Tenatoprazole Enantiomers Using High Performance Liquid Chromatography on Vacomycin-Bonded Chiral Stationary Phase,” Se Pu, Vol. 25, No. 5, 2007, pp. 732-734.
|
[3]
|
K. Uchiyama, D. Wakatsuki, B. Kakinoki, Y. Takeuchi, T. Araki and Y. Morinaka, “The Long-Lasting Effect of TU-199, a Novel H+, K+ -ATPase Inhibitor, on Gastric Acid Secretion in Dogs,” Journal of Pharmacy and Pharmacology, Vol. 51, No. 4, 1999, pp. 457-464. doi:10.1211/0022357991772510
|
[4]
|
A. H. Chun, K. Erdman, Y. Zhang, R. Achari and J. H. Cavanaugh, “Effect on Bioavailability of Admixing the Contents of Lansoprazole Capsules with Selected Soft F- oods,” Clinical Therapeutics, Vol. 22, No. 2, 2000, pp. 231-236. doi:10.1016/S0149-2918(00)88481-7
|
[5]
|
C. Larson, N. J. Cavuto, D. A. Flockhart and R. B. Weinberg, “Bioavailability and Efficacy of Omeprazole Given Orally and by Nasogastric Tube,” Digestive Diseases and Sciences, Vol. 41, No. 3, 1996, pp. 475-479. doi:10.1007/BF02282321
|
[6]
|
J. P. Galmiche, S. B. des Varannes, P. Ducrotte, S. Sacher-Huvelin, F. Vavasseur, A. Taccoen, P. Fiorentini and M. Homerin, “Tenatoprazole, a Novel Proton Pump Inhibitor with a Prolonged Plasma Half-Life: Effects on Intragastric pH and Comparison with Esomeprazole in Healthy Volunteers,” Aliment Pharmacology and Therapeutics, Vol. 19, No. 6, 2004, pp. 655-662. doi:10.1111/j.1365-2036.2004.01893.x
|
[7]
|
R. Nirogi, V. Kandikere, K. Mudigonda and G. Bhyrapuneni, “Quantification of Tenatoprazole in Rat Plasma by HPLC: Validation and Its Application to Pharmacokinetic Studies,” Biomedical Chromatography, Vol. 21, No. 12, 2007, pp. 1240-1244.doi:10.1002/bmc.875
|
[8]
|
P. Liu, B. Sun, X. Lu, F. Qin and F. Li, “HPLC Determination and Pharmacokinetic Study of Tenatoprazole in Dog Plasma after Oral Administration of Enteric-Coated Capsule,” Biomedical Chromatography, Vol. 21, No. 1, 2007, pp. 89-93. doi:10.1002/bmc.724
|
[9]
|
F. Domagala, H. Ficheux, G. Houin and J. Barre, “Pharmacokinetics of Tenatoprazole, a Newly Synthesized proton Pump Inhibitor, in Healthy Male Caucasian Vlunteers,” Arzneimittel Forschung, Vol. 56, 2006, pp. 33-39.
|
[10]
|
M. Mahadik, V. Bhusari, M. Kulkarni and S. Dhaneshwar, “LC-UV and LC-MS Evaluation of Stress Degradation Behavior of Tenatoprazole,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 50, No. 5, 2009, pp. 787-793. doi:10.1016/j.jpba.2009.06.026
|
[11]
|
ICH, “Q2 (R1) Validation of Analytical Procedures: Text and Methodology,” International Conference on Harmonization, Geneva, November 2005, pp. 1-13.
|
[12]
|
P. Lindberg, A. Brandstrom, B. Wallmark, H. Mattsson, L. Rikner and K. J. Hoffmann, “Omeprazole: The First Proton Pump Inhibitor,” Medical Care Research and Review, Vol. 10, No. 1, 1990, pp. 1-54.
|